Abstract
Using a new immunoradiometric assay (ELSA pS2 Cis-France), a total of 200 cytosols obtained from primary breast tumors were examined for pS2 content, which is an estrogen-regulated protein actually studied as a marker of hormone sensitivity and favorable prognostic factor in breast cancer. In our patient group, the median pS2 value corresponding to 5.3 ng/mg of cytosolic proteins was used as cutoff. pS2 content was not related to menopause status, tumor size, or nodal involvement, whereas a positive correlation was found between pS2 and ER/PgR status. Moreover, the association of pS2 with steroid receptors seems to identify subgroups of patients better than ER/PgR alone.
MeSH terms
-
Adult
-
Aged
-
Aged, 80 and over
-
Antibodies, Monoclonal* / immunology
-
Antibodies, Monoclonal* / metabolism
-
Biomarkers* / analysis
-
Breast Neoplasms / diagnosis*
-
Breast Neoplasms / physiopathology
-
Carcinoma / diagnosis*
-
Carcinoma / physiopathology
-
Cytosol / chemistry
-
Estrogens / physiology
-
Female
-
Humans
-
Immunoradiometric Assay
-
Middle Aged
-
Multiple Chemical Sensitivity
-
Neoplasm Proteins* / blood
-
Neoplasm Proteins* / immunology
-
Prognosis
-
Proteins*
-
Receptors, Estrogen / physiology
-
Receptors, Progesterone / physiology
-
Trefoil Factor-1
-
Tumor Suppressor Proteins
Substances
-
Antibodies, Monoclonal
-
Biomarkers
-
Estrogens
-
Neoplasm Proteins
-
Proteins
-
Receptors, Estrogen
-
Receptors, Progesterone
-
TFF1 protein, human
-
Trefoil Factor-1
-
Tumor Suppressor Proteins